logo
ProjectOngoing

Regulation of NK cell function

Location: Germany

Source: EU Funding & Tenders Portal

The human immune system has evolved sophisticated mechanisms to recognize and eliminate infected, stressed or cancer cells. Presentation of antigens by HLA-I enables the identification of diseased cells by antigen-specific T cells, while changes in HLA-I expression levels are sensed by NK cells. Many human NK cell receptors bind HLA-I; but whether and how NK cells might interact with HLA-II remain

Status
Under Construction
Location
Germany
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Regulation of NK cell function

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Regulation of NK cell function” is an infrastructure initiative, located in Germany. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The human immune system has evolved sophisticated mechanisms to recognize and eliminate infected, stressed or cancer cells. Presentation of antigens by HLA-I enables the identification of diseased cells by antigen-specific T cells, while changes in HLA-I expression levels are sensed by NK cells. Many human NK cell receptors bind HLA-I; but whether and how NK cells might interact with HLA-II remained unknown. We recently discovered that a subset of commonly expressed HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44, implicating HLA-II in the regulation of NK cells. Remarkably, the strength of NKp44-binding to HLA-DP was dependent on both the HLA-DP allotype and the HLA-DP-presented peptide. The ability of NK cell receptors to bind HLA-II molecules represents a paradigm shift from previous models describing NK cell function largely in the context of HLA-I, and suggests a novel regulatory framework in which NK cells interact directly with HLA-II-expressing cells, including APCs and activated stroma cells. HLA-DP allotypes have been associated with the incidence and outcome of several infectious and inflammatory diseases, and the newly identified interactions between HLA-DP and NKp44 now provide a molecular mechanism implicating NK cells in the pathogenesis of these diseases. As NKp44 and HLA-DP are not expressed in mice, but have evolved recently in primates and humans, studies investigating the underlying mechanisms have to be performed in humans. The applicant proposes an innovative and integrated research program, combining functional immunological and virological approaches with recently developed human organoid systems and proteomics technologies to investigate the impact of interactions between NKp44 and HLA-DP for human diseases, with the ultimate goal to harness NK cells for immunotherapeutic interventions against infections and inflammatory diseases.

Location

Country

Germany

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2025-10-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project